Anne Kroman1, Basil Saour1, Jordan M Prutkin2. 1. Division of Cardiology, Section of Electrophysiology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA. 2. Division of Cardiology, Section of Electrophysiology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA. jprutkin@cardiology.washington.edu.
Abstract
PURPOSE OF REVIEW: Leadless pacemakers were developed to reduce complications associated with transvenous pacemaker implant and long-term follow-up. Since initial market release, however, there have been registry and single-center reports documenting improvements in implant technique, reduced complication rates, and new patient populations studied. RECENT FINDINGS: Most studies have demonstrated a further reduction in complication rates and safe implant in those on continuous anticoagulation. Perforation rates are decreasing but still occur and risk factors include BMI < 20 kg/m2, age ≥ 85 years, females, history of heart failure, indication not including atrial fibrillation, and chronic lung disease. Device infections are exceedingly rare, even in those undergoing infected transvenous devices at the same time. For appropriate patients, leadless pacing is a safe and reasonable option, especially if atrial-based sensing or pacing is not needed. Future iterations may include VDD pacing, atrial pacing, dual-chamber pacing, biventricular pacing, and device-device communication.
PURPOSE OF REVIEW: Leadless pacemakers were developed to reduce complications associated with transvenous pacemaker implant and long-term follow-up. Since initial market release, however, there have been registry and single-center reports documenting improvements in implant technique, reduced complication rates, and new patient populations studied. RECENT FINDINGS: Most studies have demonstrated a further reduction in complication rates and safe implant in those on continuous anticoagulation. Perforation rates are decreasing but still occur and risk factors include BMI < 20 kg/m2, age ≥ 85 years, females, history of heart failure, indication not including atrial fibrillation, and chronic lung disease. Device infections are exceedingly rare, even in those undergoing infected transvenous devices at the same time. For appropriate patients, leadless pacing is a safe and reasonable option, especially if atrial-based sensing or pacing is not needed. Future iterations may include VDD pacing, atrial pacing, dual-chamber pacing, biventricular pacing, and device-device communication.
Authors: Vivek Y Reddy; Derek V Exner; Daniel J Cantillon; Rahul Doshi; T Jared Bunch; Gery F Tomassoni; Paul A Friedman; N A Mark Estes; John Ip; Imran Niazi; Kenneth Plunkitt; Rajesh Banker; James Porterfield; James E Ip; Srinivas R Dukkipati Journal: N Engl J Med Date: 2015-08-30 Impact factor: 91.245
Authors: Paul R Roberts; Nicolas Clementy; Faisal Al Samadi; Christophe Garweg; Jose Luis Martinez-Sande; Saverio Iacopino; Jens Brock Johansen; Xavier Vinolas Prat; Robert C Kowal; Didier Klug; Lluis Mont; Jan Steffel; Shelby Li; Dirk Van Osch; Mikhael F El-Chami Journal: Heart Rhythm Date: 2017-05-11 Impact factor: 6.343
Authors: Alexander Kypta; Hermann Blessberger; Juergen Kammler; Michael Lichtenauer; Thomas Lambert; Rene Silye; Clemens Steinwender Journal: Can J Cardiol Date: 2015-12-29 Impact factor: 5.223
Authors: Alexander Kypta; Hermann Blessberger; Juergen Kammler; Thomas Lambert; Michael Lichtenauer; Walter Brandstaetter; Michael Gabriel; Clemens Steinwender Journal: J Cardiovasc Electrophysiol Date: 2016-07-27
Authors: Pamela Omdahl; Michael D Eggen; Matthew D Bonner; Paul A Iaizzo; Kent Wika Journal: Pacing Clin Electrophysiol Date: 2016-02-01 Impact factor: 1.976